Vacuum-drying of PURASORB PLG 8218 before monofilament absorbable suture extrusion is performed at 40–45 °C and 10 mbar for a minimum of 16 h to bring residual moisture below 0.02 wt%, because the 82:18 lactide-glycolide backbone hydrolyzes rapidly at melt-processing temperatures when water is not removed. Pellets are then fed into a 25 mm single-screw extruder with an L/D ratio of 24:1 using barrel zone set points of 145/150/155/160 °C from feed to die; the die is maintained at 160 °C and melt pressure is limited to 80–120 bar to avoid shear-induced chain scission. The extrudate is quenched in a 20 °C water bath and drawn through a heated godet at 55–65 °C to a total draw ratio between 4.0 and 4.8. Annealing at 60 °C for 5 h stabilizes orientation while the 82:18 ratio suppresses crystallization compared with higher-lactide PLG grades. Amine-containing additives or functional masterbatch carriers are not used in the feed stream because residual basic species accelerate autocatalytic hydrolysis of the ester bonds; any external lubricant is restricted to a fully refined medical white oil at 0.05–0.15 wt%. Finished monofilament is evaluated for knot-pull and straight-pull tensile per ASTM D2256-21 and for local tissue response per ISO 10993-6. Cytotoxicity per ISO 10993-5:2009, sensitization per ISO 10993-10, and systemic toxicity per ISO 10993-11 are applied as part of the ISO 10993-1:2018 biological evaluation. Degradation screening is carried out in phosphate-buffered saline at 37±1 °C per ASTM F1635-16, with residual lactide measured by GC-FID and kept at release below 0.5 wt%.

Does Solvent Evaporation Microencapsulation of PLG 8218 Require Residual Dichloromethane Control Under ICH Q3C?

Microsphere-based long-acting injectable depots built from the 82:18 lactide-glycolide ratio require control of dispersed-phase composition rather than simply residual solvent. In an oil-in-water solvent-evaporation process, PURASORB PLG 8218 is dissolved in dichloromethane at 12–18 wt%, and the solution is emulsified into an aqueous continuous phase containing 1.0 wt% poly(vinyl alcohol) with a hydrolysis degree of 87–89% and molecular weight from 13,000 to 23,000 under a rotor-stator high-shear mixer operating at 10,000–14,000 rpm. The primary emulsion is then transferred to a stirred extraction tank where water is added to lower dichloromethane concentration and harden the microspheres; stirring time and solvent-exchange rate control mean particle size. Collected microspheres are wet-sieved to a target range of 20–80 µm and lyophilised. Residual dichloromethane is measured by headspace GC-FID per ICH Q3C, with a Class 2 permissible concentration of 600 ppm and 6.0 mg/day as the acceptable exposure basis. If the continuous phase is not replaced over 3–5 extraction cycles, residual surfactant on the polymer surface reaches levels that suppress the burst-free release profile. The terminal finished product is a sterile, injectable powder for reconstitution; particulate matter is controlled per USP 788 with the small-volume parenteral limit of 6000 particles ≥10 µm and 600 particles ≥25 µm per container. Gamma sterilisation is avoided unless validated at low dose because 25 kGy irradiation of dry PLG 8218 measurably lowers inherent viscosity; aseptic manufacturing under ISO 13485 with continuous environmental monitoring is therefore the preferred route for this product class.

After injection moulding of PURASORB PLG 8218 into resorbable interference screws, the dominant process conflict is not cavity fill but monomer generation at high barrel residence time. The 82:18 molar ratio lowers the glass transition to approximately 50 °C, but the dry polymer is still run from a desiccant hopper into a 25–35 mm injection unit with barrel zones from 150 °C to 175 °C. If the residence time exceeds 10–12 min, melt viscosity drops, short-shot margins narrow, and lactide monomer is detectable by GC-FID; screw back pressure is therefore held at 15–30 bar and the cushion at 3–5 mm. Mould temperature is controlled at 20–30 °C to limit slow crystallisation and warpage; the screw thread core needs 2–4 °C chromed cooling channels because frozen PLG 8218 releases from polished surfaces with high ejection force. Drying above 50 °C in a desiccant air dryer is avoided because particle agglomeration occurs before the melt phase. Finished screws are tested in torsion using ASTM F2502-17, which covers absorbable polymer fixation implants, and in vitro mass loss and pH change are tracked by ASTM F1635-16. The terminal device must meet ISO 10993-1:2018 biological evaluation for long-term implantation, including genotoxicity per ISO 10993-3, local effects after implantation per ISO 10993-6, and subchronic systemic toxicity per ISO 10993-11. For anterior cruciate ligament interference screws with a diameter of 9 mm, published data for this specific polymer configuration is limited, and batch-to-batch torque data from production-scale moulding should be used to set the release specification rather than extrapolating from lower-lactide PLGA grades.

Low-Dose Drug-Eluting Stent Coatings Demand a Sub-15 µm Dry Film and High Adhesion on Cobalt-Chromium

Coating solution design for PURASORB PLG 8218 on a cobalt-chromium coronary stent begins with 1.0–2.0 wt% polymer in a 70:30 v/v ethyl acetate/acetone mixture; this solvent composition avoids boiling-point excursion during ultrasonic nozzle atomisation at 40–60 kHz. The target dry coating thickness is below 15 µm across the abluminal surface, because thicker PLG 8218 films crack during balloon expansion and crimping. A nitrogen-purge spray system with a 0.15–0.25 mL/min flow rate and nozzle-to-stent distance of 15–25 mm deposits successive layers; each layer is flash-dried at 35–40 °C before the next pass. Coating mass per stent is monitored gravimetrically and kept within 400–800 µg depending on stent length; total drug load is then adjusted by the ratio of active pharmaceutical ingredient to PLG 8218, commonly in the range of 25–50 wt% drug. Residual peroxide in the solvent mixture is controlled to ≤5 ppm because peroxides oxidise both the drug and PLG 8218 during solvent evaporation. Adhesion is evaluated by scanning electron microscopy after crimping onto a 3.0–4.0 mm balloon catheter because detachment defects larger than 20 µm are outside the acceptance range for commercial drug-eluting stent coating layers. Hemocompatibility is assessed per ISO 10993-4, including complement activation and platelet counting in human blood contact assays; the full biological evaluation follows ISO 10993-1:2018. The terminal product is a sterile, single-use catheter-stent assembly; terminal ethylene oxide sterilisation must be followed by vacuum outgassing because PLG 8218 can retain ethylene oxide in sub-15 µm coatings above the ISO 10993-7 allowable limit if aeration is shorter than 12 h at 45 °C.

When Solvent-Cast Dental Barrier Membranes Are Annealed Below the Glass Transition, Pore Bridging Becomes the Main Yield Mode

Solvent casting of 82:18 PLG 8218 into resorbable periodontal barrier membranes creates a process boundary at the drying temperature: if the film is dried at 30 °C and then annealed at 45–50 °C, residual solvent pockets remain below the glass transition and the resulting micropores behave as crack initiators under bending. A 5.0 wt% PLG 8218 solution in 80:20 v/v ethyl acetate/acetone is cast onto a plasma-cleaned glass plate with a knife gap from 300 µm to 500 µm. The first drying stage at 25 °C and 40% RH for 30 min removes the majority of the solvent; the film is then annealed at 55–60 °C for 2 h, above the effective wet-film glass transition, to collapse the surface pores before complete solvent removal. Total residual solvent is measured by headspace GC-FID and kept below 500 ppm for acetone and 5000 ppm for ethyl acetate if ICH Q3C Class 3 limits are used as a conservative device release criterion. Terminal membrane flexibility is determined by ASTM D882-18 tensile testing at a crosshead speed of 5 mm/min; solvent-cast films without plasticiser typically report 2–8% elongation at break, and values below 2% are considered too brittle for a foldable clinical membrane. The membrane is terminally packaged as a double-pouch gamma-sterilised device per ISO 11137; the selected dose is verified to keep post-irradiation inherent viscosity within product specification. Biological evaluation includes ISO 10993-5, ISO 10993-10, and implantation studies per ISO 10993-6 in oral soft tissue for a contact duration covering resorption. Poly(ethylene glycol)-based plasticisers are not added because they leach quickly and shift the resorption profile away from the 82:18 copolymer baseline.

Supercritical Foaming Scaffold Porosity and Vent Rate Control

Tissue engineering scaffolds from 82:18 PLG 8218 are generated by supercritical carbon dioxide foaming where the depressure rate, not the saturation pressure alone, determines whether pore walls remain intact. Saturated pellets are compression-moulded into discs at 140–150 °C, then placed in a 100–250 mL high-pressure vessel at 150 bar and 35–45 °C for 4–6 h. Carbon dioxide plasticises the amorphous polymer matrix below the melt, but the polymer gains enough free volume to allow nucleation; venting at 1.0–2.0 bar/min produces interconnected pores from 150 µm to 400 µm, while faster venting above 5 bar/min causes skin densification and internal void collapse. The scaffold is characterised by micro-computed tomography for pore interconnectivity and by scanning electron microscopy for surface porosity; porosity typical of gas-foamed PLG 8218 is reported between 70% and 85%. Compression testing per ISO 604:2002 is performed after hydration in phosphate-buffered saline for 24 h at 37 °C to avoid dry-state overestimation; when pore volume exceeds 85%, the hydrated compressive modulus falls below typical load-bearing thresholds and should be confirmed on the actual porous geometry because published data for this specific configuration is limited. Cell compatibility is assessed per ASTM F2450-18 with mesenchymal stem cells, and the final sterile scaffold is terminally sterilised by ethylene oxide with aeration per ISO 10993-7 to avoid toxic residues. Cytotoxicity testing per ISO 10993-5 is conducted after sterilisation because ethylene oxide residuals and polymer degradation products may both affect L929 cell viability.